Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Cancer Vaccines01:30

Cancer Vaccines

1.3K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Metabolic control of autophagy.

Cell·2014
Same author

A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure.

Leukemia research·2014
Same author

Restoration of CFTR function in patients with cystic fibrosis carrying the F508del-CFTR mutation.

Autophagy·2014
Same author

Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy.

Nature medicine·2014
Same author

Entosis, a key player in cancer cell competition.

Cell research·2014
Same author

Cytokines reinstate NK cell-mediated cancer immunosurveillance.

The Journal of clinical investigation·2014

Related Experiment Video

Updated: Apr 23, 2026

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

1.9K

Targeting foxp1 for reinstating anticancer immunosurveillance.

Laurence Zitvogel1, Guido Kroemer2

  • 1Gustave Roussy Cancer Campus, Villejuif, France; INSERM U1015, Villejuif, France; Université Paris Sud-XI, Faculté de Médecine, Le Kremlin Bicêtre, France; Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 507, Villejuif, France.

Immunity
|September 20, 2014
PubMed
Summary

Tumor-secreted transforming growth factor beta (TGF-β) suppresses anti-tumor CD8(+) T cell immunity. This immunosuppression occurs via TGF-β-induced upregulation of the FoxP1 transcription factor in T cells.

More Related Videos

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

1.8K
Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

6.8K

Related Experiment Videos

Last Updated: Apr 23, 2026

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

1.9K
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

1.8K
Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

6.8K

Area of Science:

  • Immunology
  • Cancer Biology
  • Molecular Biology

Background:

  • Transforming growth factor beta (TGF-β) is a key immunosuppressive cytokine produced by tumors.
  • Tumor-associated immunosuppression hinders effective anti-tumor immune responses.

Purpose of the Study:

  • To investigate the mechanism by which tumor-derived TGF-β deactivates anti-tumor CD8(+) T cell responses.
  • To identify key molecular players involved in TGF-β-mediated T cell suppression.

Main Methods:

  • Analysis of T cell responses in tumor microenvironments.
  • Investigating the role of the transcription factor FoxP1 in T cell function.
  • Utilizing molecular and immunological assays to assess T cell activity and signaling pathways.

Main Results:

  • Tumor-derived TGF-β was found to directly impair the function of anti-tumor CD8(+) T cells.
  • Upregulation of the transcription factor FoxP1 in CD8(+) T cells was identified as a critical mediator of TGF-β-induced suppression.
  • FoxP1 activity was shown to be essential for the deactivation of T cell responses by TGF-β.

Conclusions:

  • Tumor-derived TGF-β actively suppresses anti-tumor CD8(+) T cell immunity.
  • The transcription factor FoxP1 is a crucial molecular target through which TGF-β exerts its immunosuppressive effects on T cells.
  • Targeting the TGF-β/FoxP1 axis may represent a therapeutic strategy to enhance anti-tumor T cell responses.